Our results indicate that RKI-1447, a Rho-associated protein kinase inhibitor (ROCKi), can inhibit the growth of SRSF2-mutated AML cells in vitro and decrease the engraftment of primary SRSF2-mutated AML cells in vivo. The gene discussed is ROCK1; the disease is acute myeloid leukemia.